Trovax, a recombinant modified vaccinia ankara virus encoding 5T4: Lessons learned and future development

Human Vaccines

Volumn 6, Issue 10, 2010, Pages 784-791

  Kim, Dae Won ^a   Krishnamurthy, Vikram ^a   Bines, Steven D ^a   Kaufman, Howard L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5T4; Clinical trials; Tumor; Vaccine; Vaccinia virus

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; OXALIPLATIN; SUNITINIB;

ANTIGEN EXPRESSION; CANCER IMMUNIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MEGADOSE; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; PROSTATE CANCER; REVIEW; VACCINE PRODUCTION;

EID: 78649369270     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.10.13144     Document Type: Review

References (55)

1. World Health Organization 2009; Report No. 297.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med 2004; 10:909-15.
3. Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther 2010; 12:77-85.
4. Schwarztentruber D. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. ASCO abstract 2009.
5. Hodi FS, O'Day S, McDermott DF, et al. Improved survival with ipilumimab in patients with metastatic melanoma. N Engl J Med 2010; In press.
6. Finn OJ. Human tumor antigens, immunosurveillance and cancer vaccines. Immunol Res 2006; 36:72-82.
7. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1988; 57:239-46. (Pubitemid 18096328)
8. Woods AM, Wang WW, Shaw DM, Ward CM, Carroll MW, Rees BR, et al. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer. Biochem J 2002; 366:353-65.
9. Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002; 1:1129-37.
10. Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 2006; 118:50-7.
11. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 1990; 61:89-95.
12. Griffiths RW, Gilham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer 2005; 93:670-7.
13. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 1995; 5:269-74.
14. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992; 66:867-9.
15. Jones H, Roberts G, Hole N, McDicken IW, Stern P. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer 1990; 61:96-100. (Pubitemid 20043553)
16. Woods AM, Wang WW, Shaw DM, Ward CM, Carroll MW, Rees BR, et al. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer. Biochem J 2002; 366:353-65.
17. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996; 68:84-92.
18. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley M, Roberts SA, Lawniczak M, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eur J Gastroenterol Hepatol 1998; 10:479-84.
19. Starzynska T, Marsh PJ, Schofield PF, Roberts SA. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994; 69:899-902.
20. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer 2002; 5:269-74.
21. Naganuma H, Kono K, Mori Y, Takayoshi S, Stern PL, Tasaka K, et al. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer. Anticancer Res 2002; 22:1033-8. (Pubitemid 34836147)
22. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996; 68:84-92.
23. + T cells. Cancer Immunol Immunother 2008; 57:833-47.
24. Smyth LJ, Elkord E, Taher TE, Jiang HR, Burt DJ, Clayton A, et al. CD8 T-cell recognition of human 5T4 oncofetal antigen. Int J Cancer 2006; 119:1638-47.
25. Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors. Curr Opin Mol Ther 2005; 7:317-25.
26. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol 2005; 32:549-55.
27. Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 1984; 311:578-9.
28. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, et al. Vaccination with a recombinant vaccinia virus encoding a "self " antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 1999; 96:2982-7.
29. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62:6944-51.
30. Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 2007; 5:60-9.
31. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997; 159:137-54.
32. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003; 100:9458-63. (Pubitemid 37033950)
33. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3:263-71.
34. Mulryan K, Ryan MG, Myers KA, Shaw D, Wang W, Kingsman SM, et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol Cancer Ther 2002; 1:1129-37.
35. + T cell dependent and antibody mediated. Cancer Immunol Immunother 2006; 55:1081-90.
36. Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008; 20:1057-66.
37. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12:3416-24. (Pubitemid 43910887)
38. Elkord E, Dangoor A, Drury NL, Harrop R, Burt DJ, Drijfhout JW, et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J Immunother 2008; 31:820-9.
39. Ramakrishnan R, Antonia S, Gabrilovich DI. Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 2008; 57:1523-9.
40. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007; 13:4487-94.
41. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008; 57:977-86.
42. Amato RJ, Drury N, Naylor S, Jac J, Saxena S, Cao A, et al. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 2008; 31:577-85.
43. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59.
44. Amato RJ, Shingler W, Naylor S, Jac J, Willis J, Saxena S, et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 2008; 14:7504-10.
45. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med 2009; 7:2.
46. Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFNalpha): a phase 2 trial. J Immunother 2009; 32:765-72.
47. Hawkins RE, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury NL, et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 2009; 32:424-9.
48. Hawkins R, Harrop R, Naylor S, Easty S. A Randomized, Double Blind, Placebo Controlled Phase III Study of MVA-5T4 in Metastatic Renal Cancer Patients. Clin Cancer Res 2010; In press.
49. th ESMO Multidisciplinary Congress, Berlin, Germany 2009.
50. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20.
51. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor mcroenvironment. Immunol Rev 2006; 213:131-45.
52. Elkord E, Dangoor A, Burt DJ, Southgate TD, Daayana S, Harrop R, et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother 2009; 58:1657-67.
53. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergisms of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32.
54. Coe D, Begom S, Addey C, White M, Dyson J, Chai JG. Depletion of regulatory T cells by antiGITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 2010; In press.
55. + T cells. Cancer Immunol Immunother 2008; 57:833-47.